Imophoron is the developer of a novel next-generation rapid-response vaccine platform, ADDomer(TM).
Imophoron has raised €4.7M across 1 funding round from 3 investors, most recently a round in Oct 2021. Based in Bristol, UK; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-10-08 | Other | €4.7M |
| Dr Jonathan Milner,Octopus Ventures,Science Creates Ventures |
| View deal → |
